KL1333

DRUG3 trials

Sponsors

Abliva AB, Pharming Technologies B.V.

Conditions

MELAS SyndromeMitochondrial DiseaseMitochondrial DiseasesMitochondrial MyopathiesMitochondrial Respiratory Chain DeficienciesPrimary Mitochondrial Disease

Phase 1

A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

CompletedNCT03888716

Abliva ABMELAS Syndrome, Mitochondrial Diseases, Mitochondrial Myopathies +1

Start: 2019-03-18End: 2021-03-16Updated: 2021-10-20

Drug-drug Interaction Study of KL1333 in Healthy Subjects

CompletedNCT04643249

Abliva ABMitochondrial Disease

Start: 2020-11-10End: 2020-12-17Updated: 2021-10-20

Phase 2

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

RecruitingNCT05650229

Pharming Technologies B.V.Primary Mitochondrial Disease

Start: 2022-12-13End: 2027-11-01Target: 180Updated: 2026-06-26